Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01666652 · ClinicalTrials.gov registry record · Phase 1
A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults
A Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT01666652 is a Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 100 participants.
The verdict
NCT01666652, a Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
The study is designed to afford a safety and immunogenicity assessment of three Tetravalent Dengue Virus-Purified Inactivated Vaccine(TDENV-PIV) vaccine candidates.
Interventions
- OTHER Phosphate buffered saline
- BIOLOGICAL 4 µg TDENV-PIV with Alum adjuvant
- BIOLOGICAL 1 µg TDENV-PIV with AS03B1 adjuvant
- BIOLOGICAL 1 µg TDENV-PIV with Alum adjuvant
- BIOLOGICAL 1 µg TDENV-PIV with AS01E1 adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2012-09 |
| Est. Completion | 2017-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01666652
The ClinicalTrials.gov registry entry for NCT01666652 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Phosphate buffered saline is the first listed.
NCT01666652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01666652 about?
NCT01666652 is a clinical study titled "A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults". The study is designed to afford a safety and immunogenicity assessment of three Tetravalent Dengue Virus-Purified Inactivated Vaccine(TDENV-PIV) vaccine candidates.
What is the current status of trial NCT01666652?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2012-09. Estimated completion is 2017-11.
What interventions are being tested in trial NCT01666652?
The interventions under investigation include: Phosphate buffered saline (OTHER), 4 µg TDENV-PIV with Alum adjuvant (BIOLOGICAL), 1 µg TDENV-PIV with AS03B1 adjuvant (BIOLOGICAL), 1 µg TDENV-PIV with Alum adjuvant (BIOLOGICAL), 1 µg TDENV-PIV with AS01E1 adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT01666652?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.